联用吸入型糖皮质激素和长效β2-受体激动剂在COPD缓解期治疗中的疗效观察

Efficacy of inhaled glucocorticoids and long - acting beta 2 - agonistS inhalation in patients with stable COPD

目的 观察缓解期慢性阻塞性肺疾病（COPD）患者吸入糖皮质激素和长效β2-受体激动剂（ICS／LABA）后对临床症状和肺功能的影响程度。方法 按照随机、对照、单盲的设计，将120例稳定期COPD患者分为两组，观察组给予舒利迭^TM（SAL／FP，50μg，2次／d）与对照组给予施立稳^TM（FP，50μg，2次/d）吸入治疗3个月，观察治疗前后测定肺功能第1秒用力呼吸气量占预计值的百分比、用力肺活量，并记录临床症状评分。结果 观察组COPD患者吸入SAL／FP治疗后，临床症状积分和肺功能指标差异有统计学意义（P〈0．01），与对照组比较差异有统计学意义（P〈0．05）。结论 联合应用吸入型糖皮质激素和长效β2-受体激动剂用于缓解期COPD患者的治疗及预防，对缓解症状和改善肺功能均能收到良好效果，且较单用长效β2-受体激动剂疗效好（P〈0．05）。

Objective To observe the effect of inhaled glucocorticoids and long - acting beta 2 - ago- nist＇s inhalation （LABA/ICS） on symptom and lung function of patients in stable chronic obstructive pulmonary disease（COPD）. Methods 120 cases stable COPD patients were randomly divided into two groups. The observation group was given seretide^TM （SAL/FP Powder ： 50μg. Bid） and the control group was given serevent^TM （FP Powder：50μg. Bid） for 3 months inhalation treatment. Rate of forced expiratory volume （ FEV1% ） and forced vital capacity （ FVC ） were observed as well as the clinical symptoms. Resuits In observation group, the clinical symptoms and lung function were significantly changed after the stable COPD patients inhaled the SAL/FP（ P 〈0.01 ）. The statistical significance were observed in the lung function and clinical symptoms between the two groups（ P 〈 0.05 ）. Conclusion Inhaled glucocorticoids and long - acting beta 2 - agonist＇s inhalation has the better effect on treatment and prevention of patients in stable COPD than only inhaled long - acting beta 2 - agonist＇s inhalation, especially benefit to symptom control and improvement of lung function （ P 〈 0.05 ）.